《2015年美国宫颈癌筛查过渡期临床指南》解读

Interpretation of 2015 Interim Clinical Guidance for American Cervical Cancer Screening

宫颈癌已成为全球女性重要的疾病负担,高危型人乳头状瘤病毒(HPV)持续性感染是导致其发生的主要因素。目前,美国宫颈癌的主要筛查方案为细胞学筛查及细胞学与高危型HPV结合的联合筛查方案。《2015年美国宫颈癌筛查过渡期临床指南》提出高危型HPV检测可以单独作为宫颈癌初筛方案之一,也可以作为细胞学以及细胞学和高危型HPV联合筛查的替代方案。为了更好地理解该指南,现对指南的制定背景、主要相关内容及相关内容的制定依据进行解读。

Cervical cancer is an important disease burden of women in the world. The persistent infection of high-risk HPV（HR-HPV） is one of major factors of cervical cancer. At present,the major methods of cervical cancer screening in the United States are the cervical cytology testing and the co-screening with cytology and HR-HPV testing. HR-HPV testing alone could be one of the primary screening methods for cervical cancer, which is proposed by the 2015 American Interim Clinical Guidance. HR-HPV testing alone could be a alternative strategy for the cytology testing and the co-screening. We herein interpret the background,main content and evidence of this guidance.